L
Laurence Leenhardt
Researcher at University of Paris
Publications - 128
Citations - 6393
Laurence Leenhardt is an academic researcher from University of Paris. The author has contributed to research in topics: Thyroid cancer & Thyroid. The author has an hindex of 32, co-authored 111 publications receiving 5149 citations. Previous affiliations of Laurence Leenhardt include Pierre-and-Marie-Curie University & French Institute of Health and Medical Research.
Papers
More filters
Journal ArticleDOI
European Thyroid Association Guidelines for Ultrasound Malignancy Risk Stratification of Thyroid Nodules in Adults: The EU-TIRADS
Gilles Russ,Steen Joop Bonnema,Murat Faik Erdogan,Cosimo Durante,Rose Ngu,Laurence Leenhardt +5 more
TL;DR: The novel European Thyroid Imaging and Reporting Data System, called EU-TIRADS, aims to serve physicians in their clinical practice, to enhance the interobserver reproducibility of descriptions, and to simplify communication of the results.
Journal ArticleDOI
Strategies of Radioiodine Ablation in Patients with Low-Risk Thyroid Cancer
Martin Schlumberger,B. Catargi,Isabelle Borget,Désirée Deandreis,Slimane Zerdoud,B. Bridji,Stéphane Bardet,Laurence Leenhardt,Delphine Bastie,Claire Schvartz,Pierre Vera,Olivier Morel,Danielle Benisvy,Claire Bournaud,Fran ccoise Bonichon,C. Dejax,Marie-Elisabeth Toubert,Sophie Leboulleux,Marcel Ricard,Ellen Benhamou +19 more
TL;DR: The use of recombinant human thyrotropin and low-dose (1.1 GBq) postoperative radioiodine ablation may be sufficient for the management of low-risk thyroid cancer.
Journal ArticleDOI
2018 European Thyroid Association Guideline for the Management of Graves' Hyperthyroidism
TL;DR: If a patient relapses after completing a course of ATD, definitive treatment is recommended; however, continued long-term low-dose MMI can be considered, and steroid prophylaxis is warranted in Graves’ patients with mild/active orbitopathy receiving RAI.
Journal ArticleDOI
Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial
Sophie Leboulleux,Lars Bastholt,Thomas Michael Krause,Christelle De La Fouchardiere,Jan Tennvall,Ahmad Awada,José Manuel Gómez,Françoise Bonichon,Laurence Leenhardt,Christine Soufflet,Muriel Licour,Martin Schlumberger +11 more
TL;DR: Vandetanib is the first targeted drug to show evidence of efficacy in a randomised phase 2 trial in patients with locally advanced or metastatic differentiated thyroid carcinoma, and it is believed that further investigation of tyrosine-kinase inhibitors in this setting is warranted.
Journal ArticleDOI
Indications and Limits of Ultrasound-Guided Cytology in the Management of Nonpalpable Thyroid Nodules
Laurence Leenhardt,Gilles Hejblum,Brigitte Franc,Laurence Du Pasquier Fediaevsky,Thierry Delbot,Danièle Le Guillouzic,Fabrice Menegaux,Claudine Guillausseau,Catherine Hoang,Gérard Turpin,André Aurengo +10 more
TL;DR: Indication of US-FNAB appears judicious in centimetric or supracentimetric nodules or in solid and hypoechoic ones, and such a management would allow the discovery of 15 of 20 carcinomas and would avoid 16% of unnecessary biopsies.